（文章来源：每日经济新闻） 每经AI快讯，1月21日，上海谊众(688091.SH)公告称，预计2025年度归属于上市公司股东的净利润为 6,000万元到7,000万元，比上年同期增长760.18%到903.54%。业绩变动原因：核心产品紫杉醇胶束于 2025年正式纳入国家医保目录，市场准入与用药人数大幅提高，带动营收与利润显著增长。 ...

南财智讯1月21日电，上海谊众发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 6000万元—7000万元，同比预增760.18%—903.54%；预计2025年全年归属于上市公司股东的扣除非经 常性损益的净利润为5600万元—6600万元，同比预增1338.87%—1595.81%，归属于上市公司股东的净 利润变动原因：公司核心产品注射用紫杉醇聚合物胶束（以下简称"紫杉醇胶束"）于2025年正式纳入国 家医保目录，在市场准入与用药人数上大幅提高，带动了公司全年营收与利润相较于2024年显著增长。 ...

上海谊众公告，预计2025年度实现归属于母公司所有者的净利润为6000万元到7000万元，与上年同期相 比，增长760.18%到903.54%。公司核心产品注射用紫杉醇聚合物胶束于2025年正式纳入国家医保目 录，在市场准入与用药人数上大幅提高，带动了公司全年营收与利润相较于2024年显著增长。 ...

证券之星消息，1月19日化学制药板块较上一交易日下跌0.68%，上海谊众领跌。当日上证指数报收于 4114.0，上涨0.29%。深证成指报收于14294.05，上涨0.09%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300111 | 向日葵 | 4.88 | 19.90% | 252.73万 | | 11.30亿 | | 600774 | 汉商集团 | 10.58 | 9.98% | 17.68万 | | 1.78亿 | | 688759 | 必贝特 | 52.00 | 8.02% | 5.92万 | | 3.07亿 | | 300086 | 康艺药业 | 11.09 | 7.88% | 62.96万 ﺎ | | 6.79亿 | | 300497 | 富祥药业 | 17.37 | 4.89% | 59.79万 | | 10.41亿 | | 002826 | 易明医药 | 19.14 | 4.65% | 11.34万 | | 2.17亿 | | ...

证券之星消息，1月9日化学制药板块较上一交易日上涨1.77%，前沿生物领涨。当日上证指数报收于 4120.43，上涨0.92%。深证成指报收于14120.15，上涨1.15%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688221 | 前沿生物 | 28.15 | 19.99% | 30.53万 | | 7.86亿 | | 688091 | 上海谊众 | 60.84 | 17.29% | 11.94万 | | 6.88亿 | | 688658 | 悦康药业 | 31.79 | 17.13% | 20.04万 | | 5.86亿 | | 600513 | 联环药业 | 21.11 | 10.01% | 1 30.53万 | | 6.20亿 | | 601089 | 福元医药 | 30.27 | 9.99% | 10.86万 | | 3.10亿 | | 688356 | 键凯科技 | 101.00 | 8.57% | 3.59万 | | 3.51亿 ...

Core Viewpoint - The pharmaceutical sector is experiencing significant stock price increases, with notable gains in several companies, indicating positive market sentiment and potential investment opportunities [1]. Group 1: Company Performance - Weikang Pharmaceutical has seen its stock price rise by over 15% [1]. - Frontline Bio and Shanghai Yizhong have both increased by over 10% [1]. - Other companies such as Lianhuan Pharmaceutical, Hongbo Pharmaceutical, Zhixiang Jintai, and Chengda Pharmaceutical are also experiencing upward trends in their stock prices [1].

Core Viewpoint - The innovative drug sector experienced a significant rally, with notable stock price increases among various companies [1] Group 1: Company Performance - Weikang Pharmaceutical saw its stock price rise by over 18% [1] - Qianfang Bio and Shanghai Yizhong both increased by more than 10% [1] - Other companies such as Lianhuan Pharmaceutical, Hongbo Pharmaceutical, Zhixiang Jintai, and Chengda Pharmaceutical also experienced upward movement in their stock prices [1]

Group 1 - Shanghai Yizhong Pharmaceutical Co., Ltd. has seen its stock price increase by 6.03% to 55.00 CNY per share, with a total market capitalization of 11.369 billion CNY as of January 9 [1] - The company has experienced a continuous stock price increase for six days, with a cumulative increase of 11.45% during this period [1] - The main business of Shanghai Yizhong involves the research and industrialization of modified new anti-tumor drugs, with 99.84% of its revenue coming from injectable paclitaxel polymer micelles [1] Group 2 - Huashan Fund holds a significant position in Shanghai Yizhong, with its Huashan CSI 1000 Index Enhanced A Fund (015148) owning 3,962 shares, representing 0.4% of the fund's net value [2] - The fund has generated a floating profit of approximately 12,400 CNY today and a total of 21,100 CNY during the six-day stock price increase [2] - The Huashan CSI 1000 Index Enhanced A Fund was established on July 12, 2022, with a current scale of 45.938 million CNY and a year-to-date return of 5.53% [2]

Group 1 - The chemical pharmaceutical sector increased by 0.24% on January 8, with Bibete leading the gains [1] - The Shanghai Composite Index closed at 4082.98, down 0.07%, while the Shenzhen Component Index closed at 13959.48, down 0.51% [1] - Notable gainers in the chemical pharmaceutical sector included Bibete, which rose by 20.00% to a closing price of 49.68, and Qijingt, which increased by 10.00% to 28.27 [1] Group 2 - The chemical pharmaceutical sector experienced a net outflow of 191 million yuan from institutional investors, while retail investors saw a net inflow of approximately 84.42 million yuan [2] - The trading volume for Bibete was 140,500 shares, with a transaction value of 682 million yuan, indicating strong market interest [1] - The sector's overall trading activity showed a mix of inflows and outflows, with specific stocks like Hainan Haiyao and Xinyu Pharmaceutical seeing significant institutional interest [3]

Market Overview - The Shanghai Composite Index closed at 4089.45 points, above the annual line, with a slight increase of 0.09% [1] - The total trading volume of A-shares reached 17815.48 billion yuan [1] Stocks Breaking Annual Line - A total of 124 A-shares have surpassed the annual line today, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - Keta Power (300153) with a deviation rate of 11.05% and a daily increase of 12.50% [1] - Tianjian Technology (002977) with a deviation rate of 9.75% and a daily increase of 10.00% [1] - Hongbo Pharmaceutical (301230) with a deviation rate of 9.27% and a daily increase of 10.27% [1] Additional Stocks with Notable Performance - Other stocks with significant performance include: - Hongdu Aviation (600316) with a daily increase of 8.58% and a deviation rate of 8.08% [1] - Jiuliang Co. (300808) with a daily increase of 5.79% and a deviation rate of 5.21% [1] - Zhongcheng Technology (920207) with a daily increase of 22.67% and a deviation rate of 4.84% [1] Summary of Stocks with Smaller Deviation Rates - Stocks that have just crossed the annual line with smaller deviation rates include: - Dongfang Guoxin (东方国信) and Fuchun Environmental (富春环保) with minimal deviation rates [1] - The table lists various stocks along with their daily performance metrics, including turnover rates and latest prices [1]